November 11th 2024
Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.
October 31st 2024
Your daily dose of the clinical news you may have missed.
October 29th 2024
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
October 9th 2024
Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.
October 8th 2024
Severe Asthma Research Quiz: 8 Questions on Notable New Findings
New study findings on asthma exacerbation risk prediction, rapid steroid reduction, and patient perception of disease lead this quick quiz.
Racial/Ethnic Bias Found in Asthma Clinical Trials Used to Update NHLBI Guideline
In the majority of studies that reported racial/ethnic data, White participants were highly overrepresented and Black/Hispanic/all Other underrepresented.
Severe Asthma Research Recap: 8 Updates for Primary Care
Research summaries on GINA revisions, a steroid-reduction algorithm, factors that predict asthma exacerbation risk, and more.
New Study Identifies Key Risk Factors Likely to Accelerate a COPD Diagnosis in Patients with Asthma
New research highlights several key risk factors that are likely to accelerate the progression from asthma to COPD, including older age and prior tobacco use.
Severe Uncontrolled Asthma: 5 Questions on Key Characteristics
Optimal use of biologic therapy for severe uncontrolled asthma rests on understanding of the disease itself. Try this quick quiz to test your knowledge.
Tezepelumab Reduces Exacerbations in Patients with Severe Asthma Regardless of Season
New data from the phase 3 NAVIGATOR trial demonstrate superior efficacy of tezepelumab to reduce asthma exacerbations in severe disease year round.
Workplace Pesticide Exposure Tied to Higher Risk of COPD, Suggests New Study
Occupational exposure to pesticides was linked to an increased risk of COPD in a large UK study.
Omicron Subvariant BA.2: What We Know Now
Known as BA.2, the new Omicron subvariant is now circulating at low levels in the US. What can you tell your patients? Here's what we know, now.
7 COVID-19 Home Test Kits Ranked by Usability
Seven at-home COVID-19 rapid tests, all available online or at retail, are ranked for dexterity required, instruction legibility, and other features you may need to parse for your patients.
Pop Flu Quiz: What does the CDC say?
The CDC recommends ASAP use of antivirals in certain high-risk patient groups. Test your memory of who is in those groups with 2 short questions.
Pfizer COVID-19 Oral Antiviral Still Nearly 90% Effective Against Severe Disease
Pfizer reported today final results of the phase 2/3 EPIC-HR trial, findings that confirm the investigational drug's 89% efficacy against severe COVID-19 disease.
Guideline Toplines: 2021 Clinical Focus Collection
The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.
Influenza Virus: How well do you know this enemy?
The flu is well known to all primary care providers - but contributor Terry Brenneman, MD, created 6 questions on topics you might not ordinarily discuss. Quiz time.
Flu Season 2021-2022: Primary Care Fears & Patients on the Fence
This flu season will bring different challenges to primary care clinicians. Here, experts discuss specific barriers and best strategies to overcome them.
PCP Visits Associated with Smoking Cessation after Lung Cancer Diagnosis and Before Surgery
CHEST 2021: Among >7000 veterans diagnosed with lung cancer and scheduled for surgery, seeing a primary care doctor was linked to pre-operative quitting.
Study: Hispanic Adults, Women, and Older E-cigarette Users Face Higher Odds of Asthma and COPD
CHEST 2021: Study shows vaping raises the odds of developing asthma and COPD, especially in older adults, women, and Hispanic persons.
Biologics Reduce Severe Asthma Exacerbations in Real-world Study of Vulnerable Patients
CHEST2021: The CHRONICLE study of biologics to treat severe asthma found reductions in exacerbations of more than 50% in patient groups not included in clinical trials.
Tezepelumab May Improve Peak Expiratory Flow in Patients with Severe Asthma, Suggests Analysis of NAVIGATOR Trial
CHEST 2021: Patients with severe asthma who received tezepelumab compared with placebo demonstrated rapid improvement in morning and evening peak expiratory flow.
Phase 3 Trial Shows AZ Antibody Combination Reduces Risk of Severe COVID-19, Death in High Risk Groups
The long acting antibody combination reduced risk of severe disease or all-cause mortality by 50% in outpatients with high-risk comorbidities.
Two-dose Pfizer Vaccine Protects Against COVID-19 Hospitalization for at Least 6 Months
Two doses of the Pfizer COVID-19 vaccine also showed sustained efficacy of 93% against Delta-related hospital admission.
Janssen RSV Vaccine for Older Adults Drives Robust Cellular Immune, Humoral Response
Janssen's investigational vaccine showed efficacy of up to 80% in preventing RSV-mediated lower respiratory tract infections in older adults.
10 States with Largest COVID-19 Case Increases in the Last 7 Days
COVID-19 case increases in the past 7 days range from 100% to 3.16% among the 10 states with the most significant rises. Is your state among these?
Fixed-dose Albuterol/Budesonide Superior to Components for Asthma in Dual Phase 3 Trials
The albuterol/budesonide combination significantly reduced the risk of severe exacerbations and improved lung function in mild-to-moderate asthma.
Ivermectin Insanity
Ivermectin has shown no clinical benefit for the many viral infections it has been studied in - including COVID-19. Why are patients buying it and physicians prescribing it?
Smoking, NSAID-exacerbated Respiratory Disease Among Risk Factors for Severe Asthma Identified in New Study
A new study found several risk factors associated with severe adult-onset asthma, including smoking, NSAID-exacerbated respiratory disease, and sibling count.
Mezopelumab Approved by FDA for Chronic Rhinosinusitis with Nasal Polyps
FDA approval of mezopelumab follows the phase 3 SYNAPSE trial in which the anti-Il-5 monoclonal antibody reduced by 57% the need for nasal polyp surgery.
FDA Accepts Tezepelumab Biologics License Application and Grants Priority Review
Tezepelumab, a novel human monoclonal antibody that shows promise to reduce exacerbations across asthma phenotypes, was granted FDA Priority Review.
The Tobacco Endgame: 4 Major Cardiology Societies Press World Governments to Act
Four major cardiology organizations stand behind increased government action to eradicate tobacco use worldwide. Click here for a summary of why, why now, and how.
ATS.2021: Tezepelumab Significantly Reduced Asthma Exacerbations Requiring Hospitalization in Phase 3 NAVIGATOR Trial
Extended Exposure to Air Pollution Raises Hospitalization Risk in COVID-19 Patients with Pre-existing Respiratory Diseases
Patients with asthma or COPD living in areas with high levels of air pollution are at an increased risk of hospitalization if they contract COVID-19, suggests a new pilot study.